These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 33319468)

  • 1. Updated meta-analysis assessing the risk of amputation with sodium-glucose co-transporter-2 inhibitors in the hallmark cardiovascular and renal outcome trials.
    Patoulias D; Papadopoulos C; Doumas M
    Diabetes Obes Metab; 2021 Apr; 23(4):1063-1065. PubMed ID: 33319468
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety and efficacy of sodium-glucose co-transporter-2 inhibitors in patients with kidney transplantation and diabetes mellitus.
    Yeggalam A; Liebich JA; Yu K; Shrestha E; Nadella S; Ahir V; Newman J; Lentine KL; Caliskan Y; Abu Al Rub F; Dhindsa S; Albert SG
    Diabetes Obes Metab; 2023 Jun; 25(6):1777-1780. PubMed ID: 36846956
    [No Abstract]   [Full Text] [Related]  

  • 3. Cardiorenal benefits of sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in type 2 diabetes without cardiovascular and renal diseases.
    Qiu M; Zhou X; Zhang M
    Diabetes Obes Metab; 2022 Mar; 24(3):575-577. PubMed ID: 34729884
    [No Abstract]   [Full Text] [Related]  

  • 4. SGLT2 inhibitors increase risk for diabetic ketoacidosis in type 2 diabetes.
    Griffin TP; Dinneen SF
    Ann Intern Med; 2020 Oct; 173(8):JC40. PubMed ID: 33075260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular protection with sodium-glucose co-transporter-2 inhibitors in type 2 diabetes: Does it apply to all patients?
    Giorgino F; Vora J; Fenici P; Solini A
    Diabetes Obes Metab; 2020 Sep; 22(9):1481-1495. PubMed ID: 32285611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meta-analysis of the hallmark cardiovascular and renal outcome trials addressing the risk for respiratory tract infections with sodium-glucose co-transporter-2 inhibitors: Implications for the COVID-19 pandemic.
    Patoulias D; Papadopoulos C; Boulmpou A; Doumas M
    Diabetes Obes Metab; 2021 Jul; 23(7):1696-1700. PubMed ID: 33606909
    [No Abstract]   [Full Text] [Related]  

  • 7. Sodium-glucose co-transporter-2 inhibitors (SGLT2i) use and risk of amputation: an expert panel overview of the evidence.
    Katsiki N; Dimitriadis G; Hahalis G; Papanas N; Tentolouris N; Triposkiadis F; Tsimihodimos V; Tsioufis C; Mikhailidis DP; Mantzoros C
    Metabolism; 2019 Jul; 96():92-100. PubMed ID: 30980838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease.
    Patorno E; Htoo PT; Everett BM; Kim SC
    Ann Intern Med; 2022 Jan; 175(1):W4. PubMed ID: 35038405
    [No Abstract]   [Full Text] [Related]  

  • 9. Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease.
    Patorno E; Htoo PT; Glynn RJ; Schneeweiss S; Wexler DJ; Pawar A; Bessette LG; Chin K; Everett BM; Kim SC
    Ann Intern Med; 2022 Jan; 175(1):W4-W5. PubMed ID: 35038404
    [No Abstract]   [Full Text] [Related]  

  • 10. Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease.
    Bepo L; Makam AN; Nguyen OK
    Ann Intern Med; 2022 Jan; 175(1):W3. PubMed ID: 35038403
    [No Abstract]   [Full Text] [Related]  

  • 11. Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease.
    Qiu M
    Ann Intern Med; 2022 Jan; 175(1):W3-W4. PubMed ID: 35038402
    [No Abstract]   [Full Text] [Related]  

  • 12. Meta-Analysis Assessing the Cardiovascular Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors in Patients With Chronic Obstructive Pulmonary Disease.
    Patoulias D; Papadopoulos C; Fragakis N; Karagiannis A; Doumas M
    Am J Cardiol; 2022 Jul; 174():188-189. PubMed ID: 35550822
    [No Abstract]   [Full Text] [Related]  

  • 13. Sodium-glucose co-transporter-2 inhibitors and atrial fibrillation in the cardiovascular and renal outcome trials.
    Okunrintemi V; Mishriky BM; Powell JR; Cummings DM
    Diabetes Obes Metab; 2021 Jan; 23(1):276-280. PubMed ID: 33001548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A hypothesis for why sodium glucose co-transporter 2 inhibitors have been found to cause genital infection, but not urinary tract infection.
    Fralick M; MacFadden DR
    Diabetes Obes Metab; 2020 May; 22(5):755-758. PubMed ID: 31943733
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical Adverse Events Associated with Sodium-Glucose Cotransporter 2 Inhibitors: A Meta-Analysis Involving 10 Randomized Clinical Trials and 71 553 Individuals.
    Lin DS; Lee JK; Chen WJ
    J Clin Endocrinol Metab; 2021 Jun; 106(7):2133-2145. PubMed ID: 33895840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risks of diabetic foot syndrome and amputation associated with sodium glucose co-transporter 2 inhibitors: A Meta-analysis of Randomized Controlled Trials.
    Li D; Yang JY; Wang T; Shen S; Tang H
    Diabetes Metab; 2018 Nov; 44(5):410-414. PubMed ID: 29506779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sodium-glucose co-transporter-2 inhibitors and major adverse limb events: A trial-level meta-analysis including 51 713 individuals.
    Huang CY; Lee JK
    Diabetes Obes Metab; 2020 Dec; 22(12):2348-2355. PubMed ID: 32744411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do SGLT2 inhibitors increase the risk of amputation? Make haste slowly.
    Vlachopoulos C; Terentes-Printzios D; Tsioufis K
    Eur Heart J; 2021 May; 42(18):1739-1741. PubMed ID: 33374009
    [No Abstract]   [Full Text] [Related]  

  • 19. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.
    Palmer SC; Tendal B; Mustafa RA; Vandvik PO; Li S; Hao Q; Tunnicliffe D; Ruospo M; Natale P; Saglimbene V; Nicolucci A; Johnson DW; Tonelli M; Rossi MC; Badve SV; Cho Y; Nadeau-Fredette AC; Burke M; Faruque LI; Lloyd A; Ahmad N; Liu Y; Tiv S; Millard T; Gagliardi L; Kolanu N; Barmanray RD; McMorrow R; Raygoza Cortez AK; White H; Chen X; Zhou X; Liu J; Rodríguez AF; González-Colmenero AD; Wang Y; Li L; Sutanto S; Solis RC; Díaz González-Colmenero F; Rodriguez-Gutierrez R; Walsh M; Guyatt G; Strippoli GFM
    BMJ; 2021 Jan; 372():m4573. PubMed ID: 33441402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The comparative cardiovascular and renal effectiveness of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A Scandinavian cohort study.
    Ueda P; Wintzell V; Dahlqwist E; Eliasson B; Svensson AM; Franzén S; Gudbjörnsdottir S; Hveem K; Jonasson C; Melbye M; Hviid A; Svanström H; Pasternak B
    Diabetes Obes Metab; 2022 Mar; 24(3):473-485. PubMed ID: 34738703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.